Brief: Sorrento Therapeutics Has Received FDA Clearance To Initiate Clinical Trials With Next Generation mRNA Vaccine Against Omicron SARS-CoV-2 Virus
06/12/2022 14:19
Dec 6 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO THERAPEUTICS HAS RECEIVED FDA CLEARANCE TO
INITIATE
CLINICAL TRIALS WITH A NEXT GENERATION MRNA (STI-1557) VACCINE
AGAINST OMICRON SARS-COV-2 VIRUS
* SORRENTO THERAPEUTICS HAS RECEIVED FDA CLEARANCE TO
INITIATE
CLINICAL TRIALS WITH A NEXT GENERATION MRNA (STI-1557) VACCINE
AGAINST OMICRON SARS-COV-2 VIRUS
Source text for Eikon: ID:nGNXyMv6V
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20